A new therapeutic approach to treat colorectal peritoneal carcinomatosis (PC) is becoming increasingly popular. Its main principle is to treat the macroscopic (visible) malignant peritoneal disease with complete cytoreductive surgery and, immediately after, to treat the remaining microscopic (non visible) malignant peritoneal disease with hyperthermic intraperitoneal chemotherapy (HIPEC).
Introduction
Peritoneal dissemination or "carcinomatosis" from colorectal carcinoma is a form of disease progression which can affect 30e40% of patients. 1,2 Natural history studies show that peritoneal carcinomatosis (PC) is uniformly fatal, with median survival not exceeding 6 months.
3 For more than a decade, as an alternative approach to overcome this disease, a handful of centers have pursued aggressive cytoreductive surgery to resect macroscopic disease as much as possible, combining it with intraperitoneal chemotherapy (initially without and then with hyperthermia), to treat any residual occult disease.
The aim of this review is to report the current status of this novel combined treatment, focusing on issues that have been solved and those which continue to pose problem and attempting to foresee future developments.
A new therapeutic concept becoming increasingly popular

Concept
In 1980, Spratt was the first to describe the combination of maximal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a recurring peritoneal pseudomyxoma, 4 but the main apostle of this method was PH Sugarbaker. 5 The main principles are: treating the macroscopic (visible) malignant peritoneal disease with complete cytoreductive surgery (CCRS), and immediately after, treating the remaining microscopic (non-visible) malignant peritoneal disease with HIPEC.
It is essential that surgery resects all tumor seeding greater than 1 mm because the chemotherapy bath cannot
